PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant
Latest Information Update: 28 Jun 2023
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PRECYCLE
- 06 Jun 2023 Results (n=412), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 16 Dec 2021 Status changed from active, no longer recruiting to discontinued due to COVID-19 pandemic, study cannot be finished in planned timeframe.
- 13 Jul 2021 Status changed from recruiting to active, no longer recruiting.